The broader outlook for the CDMO industry with small molecules is positive, and the management of Laurus Labs remains committed to its 2025 growth outlook
The board of directors of Laurus are scheduled to meet on January 24 to announce the financial results of the company for the quarter ended December 31, 2024.
The company said expectations of a better second half of the current financial year (H2FY25) is based on facility ramp up, delivery of late-phase NCE projects, and Ebitda margins improvement
Eris Lifesciences, BLS International and Five-Star Business are the other 3 smallcap stocks that look favourably placed on the technical charts in an otherwise weak market.
Individually, shares of Laurus Labs rose up to 5.55 per cent at Rs 517.90 per share, Akums Drugs and Pharmaceuticals shares locked in 5 per cent upper circuit at Rs 910.55 a piece
Stocks with long buildup in August series: Key levels to track on Voltas, Naukri and Laurus Labs as these stocks could potentially gain up to 9 per cent from present levels.
According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year
Goldman Sachs attributes India's underpenetrated CDMO and CRO market to smaller capacities, lack of Innovation with little collaboration between Industry and academia
Laurus Synthesis Private Limited has been issued a Form 483 with five observations and the company plans to address the observations within stipulated timelines.
Stocks to Watch on December 13, 2023: PE giant Bain Capital is likely to sell up to 1.1 per cent stake in Axis Bank via a block deal, reported Moneycontrol
